학술논문
LBA75 - 18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma
Document Type
Abstract
Author
Rozeman, E.A. ; Menzies, A.M. ; Krijgsman, O. ; Hoefsmit, E.P. ; van de Wiel, B.A. ; Sikorska, K. ; Van, T.M. ; Eriksson, H. ; Bierman, C. ; Gonzalez, M. ; Shannon, K. ; Broeks, A. ; Kerkhoven, R. ; Spillane, A.J. ; Saw, R.P. ; van Akkooi, A.C.J. ; Scolyer, R.A. ; Hansson, J. ; Long, G.V. ; Blank, C.U.
Source
In Annals of Oncology October 2019 30 Supplement 5:v910-v910
Subject
Language
ISSN
0923-7534